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Vasiliki Rahimzadeh* and Gillian BartlettAbstract
Since first sequencing the human genome in 2003, emerging genetic/genomic technologies have ushered in a
revolutionary era of medicine that purports to bridge molecular biology and clinical care. The field of translational
medicine is charged with mediating this revolution. Sequencing innovations are far outpacing guidelines intended
to ease their practice-based applications, including in primary care. As a result, genomic medicine’s full integration
in primary care settings especially, has been slow to materialize. Researchers and clinicians alike face substantial
challenges in navigating contentious ethical issues raised in translation and implementation, namely preserving
the spirit of whole-person approaches to care; maintaining respect for persons and communities; and translating
genetic risk into clinical actionability. This commentary therefore explores practical barriers to, and ethical
implications of, incorporating genomic technologies in the primary care sector. These ethical challenges are both
philosophical and infrastructural. From a primary care perspective, the commentary further reviews the ethical, legal
and social implications of the Center for Disease Control’s proposed model for assessing the validity and utility of
genomic testing and family health history applications. Lastly, the authors provide recommendations for future
translational initiatives that aim to maximize the capacities of genomic medicine, without compromising primary
care philosophies and foundations of practice.
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US, whatever the limitations of genome-wide association
studies, whatever loopholes exist in the Genetic Informa-
tion Non-discrimination Act of 2008, whatever objections
the medical establishment offers to the concept of the
masses obtaining their genomic information, make no
mistake: the genomes are coming” [1].Background
Since the early stages of the Human Genome Project,
advances in high throughput sequencing have steered the
genomic revolution [2]. Once considered major bottle-
necks to expanding sequencing technology outside the
research sphere, advances in computational power [3,4],
database storage [5] and plummeting costs of whole gen-
ome and exome sequencing [6] have made genome medi-
cine a conceivable clinical reality in a matter of years.
Genomic medicine, one aspect of personalized medicine,
“is a way to customize medical care to your body’s unique
genetic makeup” [7]. It enables the development and* Correspondence: vasiliki.rahimzadeh@mail.mcgill.ca
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article, unless otherwise stated.utilization of novel clinical tools, including next generation
sequencing (NGS), to shed light on the complexities of
human pathology [8,9]. Advances in genomics demonstrate
immense promise in early prevention, characterization and
prognostication for “many Mendelian diseases for sure, but
potentially for chronic diseases as well” [10]. While current
scientific limitations prevent robust sequencing diagnostics
for most complex chronic conditions (CCCs), the growing
number of genomic/family health history applications for
cancer and some CCCs attests to progress in understand-
ing the genetic architecture associated with conditions that
are of special interest in primary care (PC) [11].
In order to begin to chart the future of integrating PC
and genomic medicine, it is worth returning the historical
bases of PC’s purposes and foundations of care. PC is an
essential component to maintaining a high-performing
healthcare system [12]. In countries with a strong PC sys-
tem, patients are more likely to receive equitable clinical
care, prevention-focused services, and experience fewer
health emergencies [12]. PC’s modern roots in the United
States can be traced to the Mills Commission Report of
1966. Approximately a decade later, the Alma Ata Confer-
ence sought to define the primary care mission anded Central Ltd. This is an Open Access article distributed under the terms of
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care priority. In its definition, the conference used ‘essen-
tial,’ ‘scientifically sound’ and ‘socially acceptable’ to
describe primary care delivery, and reinforced the impact
of primary care on cultivating self-determination and self-
reliance in health over the lifecourse [13]. The progressive
rhetoric used at Alma Ata, which promoted primary care
as a vehicle for improving health education and strength-
ening community engagement, is reflected in most con-
temporary conceptualizations of the field today.
Merging tradition and innovation
As one of the key actors in the treatment and management
of complex, chronic conditions (CCCs), PC providers are
uniquely situated to translate the benefits of routine gen-
omic profiling for a number of reasons. The routinization
of NGS as a standard of care in the diagnosis and treat-
ment of CCC’s could enhance the preventative approaches
that PC espouses by identifying genetic predispositions
earlier in life. NGS could also facilitate continuity of care
by identifying and tailoring disease management plans to
patients’ individual genomes throughout the lifecourse. In
addition, large-scale sequencing projects conducted as part
of genome-wide associated studies (GWAS) are elucidating
important genetic patterns and may aid in identifying
targeted therapies.
In addition, PC serves as a critical intermediary between
public health bodies and upper tiers of the medical institu-
tion [12]. As such, PC providers treat the most patients at
one time [14], a thus creating the largest utilization reach
for adopters of genomic medicine as well. As a result of
the ‘on-the-ground’ accessibility of PC, it is intimately em-
bedded in communities and populations and better able
to mitigate access-related disparities in health [15]. Since
PC providers are often members themselves of the com-
munities in which they serve, this influences their ability
to practice with community-specific, cultural competency
and with an understanding of the values and priorities
therein. The longitudinal relationships fostered between
PC providers and their patient attest to this [16].
Due to the contentious issues genetic/genomic infor-
mation can raise—such as patient rights ‘not to know,’
[17] disclosure of adult onset conditions in children [18]
and prenatal genetic diagnostics [19] to name a few—the
greater sociocultural understanding of place may lead to
fewer ethical dilemmas in decision-making between pa-
tients and healthcare teams. PC providers also tend to
have the role of frontline health educators, able to in-
crease genetic literacy among community members at
each rung of the socioeconomic ladder. Given public
misunderstanding of genetic determinants of health as
demonstrated in recent studies [20,21], the need for edu-
cation before swift integration of genomic medicine is
pressing.Ethical considerations for translation
ACCE model: a translation tool for primary care?
The unique facets that characterize the philosophies and
foundations of PC are also the foci of debates concern-
ing the application-based ethics of genomic medicine in
the PC clinic. These ethical considerations—though
certainly not exhaustive—appear in Table 1 and will
be discussed in turn in the following sections. This
commentary will use as a guide the ethical, legal and
social implications (ELSi) component of the ACCE
Model Project. The model—which derives it name from
the four criteria that are used as the basis for evaluation:
analytic validity, clinical validity, clinical utility and
related ethical, legal and social implications—was de-
signed by Center for Disease Control Office of Public
Health Genomics (OPHG) to facilitate policy making
around proposed uses of genetic/genomic testing in the
clinic [22]. The first publicly accessible framework for
such evaluation, the ACCE framework, now guides a
number of American and international entities on
evaluating the practical applications of emerging gen-
etic tests, and has since inspired a separate initiative
dedicated solely to genomic applications [23]. It is
based on a 44-question survey, 3 of which comprise
the ELSi evaluation (Table 2).
Impact of scientific limitations on risk and decision-
making
To date, the lack of analytical validity and clinical utility
for many NGS technologies in diagnosing or treating
CCCs simply cannot meet the current regulatory evi-
dence standards for clinical implementation—let alone
for coverage by major health insurersb [24]. Because a
vast majority of PC consultations involve management
of CCC, the power of genomic medicine in the PC clinic
relies in the ability to alter health behaviors in line with
communicated risks from genomic analyses. Despite this,
research suggests PC providers frequently lack expertise
in extrapolating clinical risk from genomic profiles, and
report feeling unprepared to incorporate genomic
medicine in routine clinical practice [25,26] due in
part to limited expertise and relevant trainingc. Both
communication and interpretation of genetic risks are
inextricably linked to bioethical principles of informed
consent and beneficence, among others. If patients
were to base clinical decisions on results from such tests,
to provide (uncertain) risk of predisposition would be neg-
ligent at best.
Personalization and respect for persons
Though the ELSi evaluation of the ACCE model offers a
useful guide for identifying pressing concerns, some are
calling the absence of a ‘personal utility’ measure a major
limitation: “Clinical utility conceived only as improved
Table 1 Summary of translation considerations for genomic medicine and primary care
Variable in translation Primary care Genomic medicine ELSi considerations
Patient population Families, communities, entire practices Single, genetically unique
patient
Respect for persons; relational decision making;
Technological
capacities
Basic, minimal Data-intensive sequencing
machines
Lack of clinical validity and utility for CCCs;
professional responsibilities, patient informed
consent, disclosure of information, interpreting
actionable genetic risks
Meeting health needs Whole-person, generalist approaches
to care; acuity to physical and psychosocial
elements of health and wellbeing
Molecular conception of
health and disease
Sociocultural and environmental understanding
health; supra-genetic determinants of health
Health information Electronic health record Electronic health record Data-intensive storage platforms needed with
controlled access; privacy concerns
Graduate and post‐
graduate training
Standardized Under development Professional responsibilities; lack of specific
expertise
Standards of care Established by professional medical bodies Under development Resource and time constraints; professional
capacities; management of incidental findings;
rights ‘not to know’
Health education Frontline health educators for global
factors of health and disease
Educators on genomic
determinants of disease
Resource and time constraints; misunderstanding
of genetic determinants of health
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ity for the patient, such as the financial and psycho-
logical benefits of resolution of an unknown diagnosis,
changes in life-style leading to overall improvements in
health, or even family planning, all of which are influ-
enced by knowledge of the genetic susceptibility of
disease” [24]. The contextual and sociocultural focus of
a proposed ‘personal utility’ measure is necessary if PC
providers are to fulfill the bioethical mandate of respect
for persons. A personal utility measure would also allow
PC providers to better assess the true value of genomic
applications in the local milieu.
Health needs beyond the genome
Other challenges in the translation process require critical
analysis of how genomic medicine problematizes some of
the foundations of the primary care philosophy, specific-
ally its commitment to whole-person approaches. Some
claim genomic technologies may even run counter to the
whole- person care approaches often used in PC [27], and
in pursuit of advanced care in the 21st century that con-
forms to “care we need and no less, the care we want and
no more” [28]. Though whole person care cannot beTable 2 Evaluation questions 42-44 of the ACCE model
ELSi evaluation
…
42 What is known about stigmatization, discrimination, privacy/
confidentiality and personal/family social issues?
43 Are there legal issues regarding consent, ownership of data
and/or samples, patents, licensing, proprietary testing,
obligation to disclose, or reporting requirements?
44 What safeguards have been described and are these safeguards
in place and effective?precisely defined—inasmuch as it reflects a professional
practice of connecting with, and recognizing the complex-
ity of, patients in their pursuit of health and wellbeing—
whole person care transcends ‘curing’ in a clinical encoun-
ter to incorporate a more humanistic and patient-centered
approach towards ‘healing’ [29]d.
Behavior modification
PC providers’ focus on the myriad influences on health
over the lifecourse, as well as tackling determinants of ill-
health, requires a longitudinal review of the genome that
may change in response to adverse life events, environ-
mental factors and/or specific health behaviors. As a re-
sult, clinical care based on discrete analyses of the genome
in moments of illness or health threatens to ignore the
changes that DNA can incur over time [30]. Furthermore,
genomic medicine may not always offer the appropriate
clinical tools to address all patient needs. With increasing
attention and funding dedicated to translating the benefits
of NGS, there is nevertheless a critical role for whole per-
son care and its focus on the supra-genetic components of
physical, mental and spiritual health: “In viewing the pa-
tient as a hub in a wheel of a complex social, psychological
and physical environment, we must attend to the impact
of a diagnosis and focus our energies on maximizing the
patient’s adjustment and coping” [31]. In this way, PC pro-
viders often address patient needs for which the genome
may not provide information on effective therapies, such
as emotional or mental health support [32,33].
Some argue genetic reductionism—generally an overre-
liance on genetic information to predict health out-
comes—is an affront to the culture of caring itself [34].
Studies on lay knowledge of genetic determinants
of health report that many patients rationalize
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lief in the deterministic nature of their genetics [35-37].
Because primary care medicine is predicated on the idea
that care is delivered through addressing an array of
health needs over the lifecourse [38], this philosophy can
challenge the strictly molecular conceptions of disease
that is often characteristic of genomic approaches.Duty to the community
The clinical reach of primary care providers often en-
compasses communities of varying sizes and structures.
The micro-communities of family units present valuable
insight into the needs of the macro-community, which
may comprise larger urban cities and towns in which
families congregate. Ideally, PC strives to bring health-
care closest to where people live and work, while
addressing the prevailing concerns associated with each in
a culturally relevant manner [39-41]. Therefore PC pro-
viders become critical intermediaries between the social
structures of place, and its impact on the health profiles of
populations within a given community. The responsi-
bility for health outcomes within communities of people
throughout the lifecourse challenges the strictly precision
care that genomic medicine promotes. Primary care pro-
viders are often charged with practicing medicine through
a population health lens as well [12], an aspect of the pro-
fession that could run counter to the strictly individualist
approach that genomic medicine espouses. Translation
should therefore aim to preserve and strengthen, as op-
posed to supplant population-based benefits of primary
care services: “Systems that integrate care both horizon-
tally for individuals, communities, and populations and
vertically for specific diseases are most likely to provide
the greatest value. Currently, vertical integration of care
for disease is rewarded and supported to a greater degree
than horizontal integration of care for people and popula-
tions” [42].Justice: resource allocation and health inequities
The heterogeneity of the PC clinic can pose operational
difficulties and resource limitations for genomic-medicine
translation initiatives [43]. Kerner et al. concur that, “most
translational research is conducted in the relatively
resource-rich infrastructures of either academic medical
centers or the biomedical industry” [44]. The authors
argue current translational research may not necessarily
reveal how related technology will perform in an under-
resourced setting, such as free community clinics. More
concerning, however, is the “new association of genomic
medicine with ‘precision medicine.’ It reinforces the
notion that absent genomic apparatuses, clinicians who
deliver healthcare are imprecise at best, and dangerous at
worst” [45,46].Although the Affordable Care Act (ACA) attempts to
remedy such health disparities through insurance reforms
applicable to all healthcare tiers, primary care expansion
will continue to be the driving force towards realizing a
more equitable healthcare system. Thus, in order to envi-
sion a primary care future where genomic medicine is a
component, researchers and practitioners alike must take
into account the influx of new patients that will now be
afforded access to this basic level of care. That is, genomic
medicine must be available and operational at the most
under-resourced and diverse primary care settings if it
hopes to prevent widening the already significant health
disparities witnessed in the U.Se.Data storage and privacy concerns
Infrastructural demands, such as establishing secure
information-sharing platforms, have also emerged in light
of the looming clinical translation [47,48]. The gate-
keeping function of PC means providers must efficiently
distribute patient health information to appropriate spe-
cialists as needed. The distribution of electronic health
records that also patients’ genomic profiles will necessarily
be data-intensive, and require sophisticated access-control
mechanisms to meet Health Insurance Portability and
Accountability Act (HIPAA) regulations.Educational pre-requisites
Public opinion indicating gross misunderstanding about
the basic science of genomic medicine necessitates edu-
cational initiatives that need to keep pace with integra-
tion efforts. The absence of such initiatives threatens to
undermine the most fundamental bioethical rights, such
as informed consent, among patients with low genetic
and health literacy. Enabling patients to act as partners
in managing their own health involves being on the
frontlines of health education, an increasingly compli-
cated effort when (questionable) medical information is
easily accessed online. More importantly, educating pa-
tients presumes that primary care providers themselves
are well versed in understanding genetic medicine in order
to make meaningful diagnoses, an assumption that is far
from current medical education reality according to recent
surveys [49].
In responding to patient inquiries about these emer-
ging innovations in medical practice, “there is substantial
reason to believe that the health care providers fielding
such questions will be primary care providers” [50]. Des-
pite potentially overwhelming the PC system with an
influx of patients and with low genetic literacy, some
warn against the dangers of allowing curious patients to
seek clinical guidance from entities outside the formal
clinical institution, such as from direct-to-consumer
entities [51,52].
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No issue illustrates the irony of “personalized” genomics
in PC better than the disclosure of incidental findings.
By nature, genetic information is both shared and identi-
fying [53]. With future standards of care based on whole
genome/exome sequencing, incidental findings will cease
to become ‘incidental,’ and non-disclosure grounds for
legal actionf. In the context of PC, the ethical and legal
obligations to disclose findings from genomic analyses
are complicated by virtue of treating multiple patients
within the same micro community. The discovery of a
clinically significant incidental finding that is actionable
yet implicates multiple members of a biologically related
family, typifies the ethical dilemmas PC physicians may
face in determining unto who their duty to inform rests.
Such situations can contribute to “personal/family social
issues” (Table 2) when care providers must manage
confidentiality obligations with multiple patients within a
familyg. In some cases, inability to interpret actual clinical
risk from genetic/genomic testing may prevent necessary
healthcare intervention (s) either immediately or in the
future. This issue is exacerbated in the absence of stan-
dards of care for many CCCs that do not yet routinize
genetic or genomic diagnostic tools.Conclusion
The primary care arena presents unique challenges to
the evaluation, diffusion and implementation of genomic
technologies [54]. The clinical landscape is in both
scientific and legislative transition, generating public
discourse on the meanings of health and healthcare.
Yet the same aspects that present limitations also ren-
der how the primary care setting is a critical forum in
which to translate the benefits of personalized medicine in
practice. Evaluating the quality of healthcare services is to
examine, among others, the purpose and avenues for their
delivery. Where genomics delivers molecular understand-
ing of determinants underlying diseases, good primary
care aims to situate this information against the sociocul-
tural backdrop in which patients live. In this way, PC
strives to appreciate the ‘whole person’ dimensions of an
individual’s health status. Therefore the authors propose
the F3 approach, a triangulated strategy to i) Focus on the
local context, ii) Forge partnerships and support iii)
Further research. In actualizing the F3 strategy, genomic
applications in the primary care setting facilitates needs-
assessments and priority setting in diverse primary care
venues. Forging partnerships between PC providers and
additional health professionals including genetic coun-
selors as well as genetic researchers, will be valuable in co-
ordinating and designing implementation strategies for
PC; because of PC’s embeddedness within communities,
promoting and supporting translation research that engagesstakeholder communities on perceptions of genomic
medicine is essential.
To a greater degree than most specialties, primary care
is charged with health education, advocacy and preven-
tion. As such, implementing genomic medicine tools
should facilitate the preservation of the whole person
care philosophy, fulfill basic principles of medical ethics,
and develop tools for translating genetic risk of common
chronic disease into clinical actionability. This process
must be strategic and specific, using translation frame-
works applicable to the unique challenges of PC if it is
to maximize benefits of genomic and personalized medi-
cine in PC.
Endnotes
aAmericans made 1 billion visits to the doctor in 2008.
Nearly 50% of visits (462 million) were to primary care
doctors [14].
bThere have been initiatives, however, to systematically
catalogue genetic variants based on their clinical action-
ability [55], and to establish which genomic testing and/
or family history applications in fact have demonstrated
sufficient evidence to warrant their implementation at
the bedside [56].
cIn one study assessing familiarity with genomic test-
ing, over 49 percent of primary care physicians admitted
their clinical training was not adequate to perform such
testing regularly [49].
dHutchinson writes, “Curing is an action carried out
by the health care practitioner to eradicate disease or
correct a problem, while healing is a process leading to a
greater sense of integrity and wholeness …The roles of
the patient and of the health care practitioner in curing
versus healing are not just different, they are diametric-
ally opposed” [29].
eGenomic medicine researcher and family physician,
Gregory Feero, shares this concern: “Personalized genom-
ics in its current form represents a potentially disruptive
technology that will both empower and imperil consumers
who are early adopters. Depending on the level of public
uptake of these services, the downstream consequences
could be profound. At a minimum, the wash of data will
stress the capacity of the current model for the provision
of genetic services and place pressure on primary care
practitioners to react to the informational barrage in a
vacuum of solid evidence-based guidelines. Given the
overall health care environment, mismanagement of this
type of genomic data could worsen the fiscal crisis and
widen health care disparities” [50].
fA recent study published by author VR testifies to the
professional complexities of disclosing incidental findings
in the context of pediatric research. Health professionals
and clinical researchers report disclosure decisions should
be context specific, relying on such information as the
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scope of professional responsibilities, and implications for
the healthcare/research system [57].
gComplexities in familial disclosure of incidental find-
ings have led to civil litigation in numerous states. One
such case, Kimberly A. Molloy v. Diane M. Meier MD
(2004), the Minnesota Supreme Court ruled that a “physi-
cian’s duty regarding genetic testing and diagnosis ex-
tended beyond the patient to biological family members
who might be harmed” [58]. Numerous wrongful birth
lawsuits filed in the United States reflect the uncer-
tainty inherent to incidental finding disclosure pol-
icies. The Ohio Supreme Court recognized a wrongful
birth claim for the first time in Schirmer V. Mt. Auburn
Obstetrics & Gynecologic Associates Inc. (2006). In this
case, the parents were permitted to sue their physician for
the (wrongful) birth of their disabled child after receiving
negligent medical advice from physicians following genetic
test results [58].
Abbreviations
ACCE: Analytic validity, Clinical validity, Clinical utility and Ethical, legal and
social considerations; CCC: Complex, chronic conditions; NGS: Next
generation sequencing; PC: Primary care.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
VR conceived the intellectual content of the article, synthesized themes in
the literature and was involved in drafting all iterative versions of the
manuscript. GB made substantial contributions to the conceptual ideas and
provided an extensive knowledge base of primary care practices and
research. GB provided final approval of the version to be published.
Both authors have read and approved the final manuscript.
Acknowledgments
The authors would like to acknowledge Yann Joly at the Centre of Genomics
and Policy for his review and conceptual contribution to the commentary.
Received: 25 February 2014 Accepted: 22 August 2014
Published: 28 August 2014
References
1. Angrist M: Only connect personal genomics and the future of American
medicine. Mol Diagn Ther 2010, 14:66.
2. Green E, Guyer M: Charting a course in genomic medicine from base
pairs to bedside. Nature 2011, 470:204–213.
3. Berger B, Peng J, Singh M: Computational solutions for omics data.
Nature 2013, 14:333–346.
4. Shadt E, Linderman MD, Sorenson J, Lee L, Nolan GP: Computational
solutions to large-scale data management and analysis. Nature 2010,
11:647–657.
5. Marusina K: Big data requires big solutions. Genet Eng Biotechnol News
2012, 32:32–40.
6. Bonetta L: Whole-genome sequencing breaks the cost barrier. Cell 2012,
141:917–919.
7. Goodman DM, Lynm C, Livingston EH: Genomic medicine. JAMA 2013,
309:1544.
8. Wenjun J: Genomic biomarkers for chronic kidney disease. Transl Res
2012, 159:290–302.
9. Scheuner MT: Delivery of genomic medicine for common chronic adult
diseases: a systematic review. JAMA 2008, 299:1320–1334.
10. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The
continuum of translation research in genomic medicine: how can weaccelerate the appropriate integration of human genome discoveries
into health care and disease prevention? Genet Med 2007, 9:667.
11. Center for Disease Control. http://www.cdc.gov/genomics/gtesting/tier.htm.
12. Starfield B, Shi L, Macinko J: Contribution of primary care to health
systems and health. Milbank Q 2005, 83:457–502.
13. United Nations: Declaration of Alma Ata. http://www.un-documents.net/
alma-ata.htm.
14. Petterson S, Liaw w, Phillips RL, Rabin DL, Meyers DS, Bazemore AW:
Projecting US primary care physician workforce needs: 2010–2025.
Ann Fam Med 2012, 10:503–509.
15. United States Department of Health and Human Services: Action Plan to
Reduce Racial and Ethnic Health Disparities: A Nation Free of Disparities in
Health and Healthcare. Washington DC: 2011.
16. Guttmacher AE, Jenkins J, Uhlman W: Genomic medicine: who will
practice it? A call to open arms. Am J Med Genet C Semin Med Genet 2001,
106:216–222.
17. Townsend A, Rousseau F, Friedman J, Adam S, Lohn Z, Birch P: Autonomy
and the patient’s right ‘not to know’ in clinical whole-genomic
sequencing. Eur J Hum Genet 2014, 22:6–11.
18. Abdul-Karim R, Berkman BE, Wendler D, Rid A, Khan J, Badgett T, Hull SC:
Disclosure of incidental findings from next-generation sequencing in
pediatric genomic research. Pediatrics 2013, 131:564–571.
19. The American College of Obstetricians and Gynecologists. http://www.
acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-
Ethics/Ethical-Issues-in-Genetic-Testing.
20. Waters EA, Muff J, Hamilton JG: Multifactorial beliefs about the role of
genetics and behavior in common health conditions: prevalence and
associations with participant characteristics and engagement in health
behaviors. Genet Med 2014. Epub ahead of print.
21. Haga SB, Barry WT, Mills R, Ginsburg GS, Svetkey L, Sullivan J, Willard HF:
Public knowledge of and attitudes towards genetics and genetic testing.
Genet Test Mol Biomarkers 2013, 17:327–335.
22. Center for Disease Control, Public Health Genomics. http://www.cdc.gov/
genomics/gtesting/ACCE/.
23. Evaluation of Genomic Applications in Practice and Prevention.
http://www.egappreviews.org/.
24. McCarthy J, McCleod HL, Ginsberg G, McCarthy J, McCleod HL, Ginsberg G:
Genomic medicine: a decade of successes, challenges, and
opportunities. Sci Transl Med 2013, 5:189sr4.
25. Ginsberg G: ‘Grand Challenges’ in the translation of genomics to human
health. Eur J Hum Genet 2008, 16:873.
26. Houwink EJ, van Luijk SJ, Henneman L: Genetic educational needs and the
role of genetics in primary care: a focus group study with multiple
perspectives. BMC Fam Pract 2011, 12:1–9.
27. Little P, Everitt H, Williamson I, Warner G, Moore M, Gould C, Ferrier K,
Payne S: Preferences of patients for patient centred approach to
consultation in primary care: observational study. BMJ 2001,
322:1–7.
28. Murphy SAR, Freed JS: Healthcare’s ascension to patient-centered
genomic care. Pers Med 2008, 5:505–509.
29. Hutchinson TA: Whole person care: encompassing the two faces of
medicine. CMAJ 2009, 180:845–846.
30. Roberts JT, Vogelstein NJ, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu
VE: The predictive capacity of personal genome sequencing. Sci Transl
Med 2012, 4:133ra58.
31. Rosenblatt DS, Fitzpatrick J: Whole person care and the revolution in
genetics. In Whole Person Care: A New Paradigm for the 21st Century.
Edited by Hutchinson T. New York, Dordrecht, Heidelberg, London:
Springer; 2011.
32. Sheldon C, Wamonsky JA, Meir R, Morries C, Finkelstein L, Sosa M:
Telephone assessment, support, and counseling for depression
in primary care medical clinics. Cogn Behav Pract 2014,
21:282–295.
33. Taylor-Brown S, Tziporah R, McDaniel SH: Chronic Illness and Primary Care:
Integrating Mental Health and Primary Care. In The Challenges of Mental
Health Caregiving. Edited by Talley RC, Fricchione GL, Druss BJ. New York:
Springer; 2014:55–79.
34. Heusser P, Scheffer C, Neumann M, Tauschel D, Edelhauser F: Towards
non-reductionistic medical anthropology, medical education and
practitioner–patient-interaction: The example of Anthroposophic
Medicine. Patient Educ Couns 2012, 89:455–460.
Rahimzadeh and Bartlett Journal of Translational Medicine 2014, 12:238 Page 7 of 7
http://www.translational-medicine.com/content/12/1/23835. Henneman L, Timmermans DRM, van der Wal G: Public attitudes toward
genetic testing: perceived benefits and objections. Genet Test 2006,
10:143.
36. Christianson CA, Powell KP, Hahn SE, Bartz D, Blanton SH, Vance JM,
Pericak-Vance M, Telfair J, Henrich VC, Genomedical Connection:
Findings from a community education needs assessment to facilitate the
integration of genomic medicine into primary care. Genet Med 2010,
12:590.
37. Smith B, Sullivan E, Bauman A, Powell-Davies G, Mitchell J: Lay beliefs
about the preventability of major health conditions. Health Educ Res 1999,
4:315–325.
38. Sturmberg JP: Primary health care organizations – through a conceptual
and a political lens. J Eval Clin Pract 2011, 17:527.
39. Pottie K, Batista R, Mayhew M, Mota L, Grant K: Improving delivery of
primary care for vulnerable migrants Delphi consensus to prioritize
innovative practice strategies. Can Fam Physician 2014,
60:e32–e40.
40. Emilio CJ, Green AR, Betancourt JR: Cross-cultural primary
care: a patient-based approach. Ann Intern Med 1999,
130:829–834.
41. Gorin AA, Wiley J, McCauley C: Steps to growing up healthy: a pediatric
primary care based obesity prevention program for young children.
BMC Public Health 2014, 14:72–82.
42. Stange KC, Ferrer RL: The paradox of primary care. Ann Fam Med 2009,
7:293–299.
43. Westfall JM, Mold J, Fagnan L: Practice-based research—“Blue Highways”
on the NIH road-map. JAMA 2007, 297:403–406.
44. Kerner J, Rimer B, Emmons K: Dissemination research and research
dissemination: how can we close the gap? Health Psychol 2005,
24:443–446.
45. National Research Council of the National Academies: Toward Precision
Medicine: Building a Knowledge Network for Biomedical Research and a New
Taxonomy of Disease. Washington, DC: National Academies Press; 2011.
46. World Economic Forum. http://www.weforum.org/content/global-agenda-
council-personalized-precision-medicine-2012.
47. Kawamoto K, Lobach DF, Willand HF, Ginsberg G: A national clinical
decision support infrastructure to enable the widespread and consistent
practice of genomic and personalized medicine. BMC Med Inform Decis
Mak 2009, 9:17.
48. Alzu’bi A, Zhou L, Valerie W: Personal genomic information management
and personalized medicine: challenges, current solutions, and roles of
HIM professionals. Perspect Health Inf Manag 2014, 11:1c.
49. Haga SB, Carrig MM, O’Daniel JM, Orlando LA, Killeya-Jones LA, Ginsberg GS,
Cho A: Genomic risk profiling: attitudes and use in personal and clinical
care of primary care physicians who offer risk profiling. J Gen Intern Med
2011, 26:835.
50. Feero GW: Genetics of common disease: a primary care priority aligned
with a teachable moment?. Genet Med 2008, 10:82.
51. Bartlett G, Avard D, Knoppers BA: A new twist on an old problem: primary
care physicians and results from direct-to-consumer genetic testing.
Person Med 2013, 10:827–833.
52. Leachman BSA, MacArthur DG, Angrist M, Gray SW, Bradbury AR,
Vorhaus DB: Direct-to-consumer genetic testing: personalized medicine
in evolution. In ASCO Education Book. American Society of Clinical
Oncology; 2011:34–40.
53. Widdows H: The Connected Self: the Ethics and Governance of the Genetic
Individual. London: Cambridge Univeristy Press; 2013.
54. Bartlett G, Rahimzadeh V, Longo C, Orlando C, Dawes M, Lachaine J,
Bochud M, Paccaud F, Bergman H, Crimi L, Issa AM: The future of genomic
testing in primary care: the changing face of personalized medicine.
Person Med. in press.
55. U.S. National Human Genome Research Institute: Characterizing and
Displaying Genetic Variants for Clinical Action Workshop. Gaithersburg,
MD: 2011.
56. Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC,
Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church
GM, Coates RJ, Collins FS, Croyle RT, Davis BR, Downing GJ, Duross A,
Friedman S, Gail MH, Ginsburg GS, Green RC, Greene MH, Greenland P,Gulcher JR, Hsu A, Hudson KL, Kardia SL, Kimmel PL, Lauer MS, et al:
The scientific foundation for personal genomics: recommendations from
a National Institutes of Health- centers for disease control and prevention
multidisciplinary workshop. Genet Med 2009, 8:559–567.
57. Rahimzadeh V, Avard D, Sénécal K, Knoppers BM, Sinnett D: To disclose, or
not to disclose? Context matters. Eur J Hum Genet 2014. Epub ahead of
print.
58. American Medical News. http://www.ama-assn.org/amednews/2008/11/10/
prsa1110.htm.
doi:10.1186/s12967-014-0238-6
Cite this article as: Rahimzadeh and Bartlett: Genetics and primary care:
where are we headed? Journal of Translational Medicine 2014 12:238.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
